Colopy Sara A, Baker Theresa A, Muir Peter
Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA.
J Am Vet Med Assoc. 2010 Feb 1;236(3):312-8. doi: 10.2460/javma.236.3.312.
To evaluate efficacy and adverse effects of leflunomide for the treatment of naturally occurring immune-mediated polyarthritis (IMPA) in dogs.
Retrospective case series.
14 dogs with cytologically confirmed IMPA.
Medical records were used to identify dogs with a diagnosis of IMPA that were treated with leflunomide. Signalment, radiographic findings, laboratory data, dosage of leflunomide, treatment duration, treatment response, and occurrence of adverse effects were determined from medical records.
Mean +/- SD initial dosage of leflunomide was 3.0 +/- 0.5 mg/kg (1.4 +/- 0.2 mg/lb) PO once daily. Treatment duration for the initial starting dosage ranged from 1 to 6 weeks. Of the 14 dogs treated with leflunomide, 8 had complete resolution of clinical signs of IMPA initially, 5 had partial response to treatment, and 1 had minimal response to treatment. Adverse effects from treatment with leflunomide were not observed during the treatment period.
Oral administration of leflunomide was a safe and effective alternative to oral administration of corticosteroids for treatment of IMPA in dogs. On the basis of findings in this study, a starting dosage for leflunomide of 3 to 4 mg/kg (1.4 to 1.8 mg/lb) PO once daily for at least 6 weeks before making dose adjustments is recommended. Dose adjustments should be based on cytologic evaluation of synovial fluid and clinical signs of IMPA. Hematologic variables, serum biochemical analysis results, and clinical signs of IMPA should be monitored for evidence of adverse effects to treatment with leflunomide.
评估来氟米特治疗犬自然发生的免疫介导性多关节炎（IMPA）的疗效和不良反应。
回顾性病例系列研究。
14只经细胞学确诊为IMPA的犬。
利用病历识别诊断为IMPA且接受来氟米特治疗的犬。从病历中确定动物特征、放射学检查结果、实验室数据、来氟米特剂量、治疗持续时间、治疗反应及不良反应的发生情况。
来氟米特的平均初始剂量为3.0±0.5mg/kg（1.4±0.2mg/lb），口服，每日1次。初始起始剂量的治疗持续时间为1至6周。在接受来氟米特治疗的14只犬中，8只最初IMPA的临床症状完全缓解，5只对治疗部分有效，1只对治疗反应轻微。治疗期间未观察到来氟米特治疗的不良反应。
口服来氟米特是治疗犬IMPA的一种安全有效的替代口服皮质类固醇的方法。根据本研究结果，建议来氟米特的起始剂量为3至4mg/kg（1.4至1.8mg/lb），口服，每日1次，至少持续6周后再进行剂量调整。剂量调整应基于滑液的细胞学评估和IMPA的临床症状。应监测血液学变量、血清生化分析结果及IMPA的临床症状，以发现来氟米特治疗不良反应的证据。
